Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995777 | 1.00 | KDM4E (0.56) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL6055303 | 0.86 | GAA (0.58) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL3003239 | 0.85 | KDM4E (0.54) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL3003242 | 0.85 | KDM4E (0.54) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL1562806 | 0.84 | SMN1; SMN2 (0.65) | KDM4ETDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL1562807 | 0.84 | SMN1; SMN2 (0.65) | KDM4ETDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL6637074 | 0.84 | SMN1; SMN2 (0.65) | KDM4ETDP1ALDH1A1MAPTKMT2A | |
| SCHEMBL31141986 | 0.83 | KDM4E (0.67) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL29158233 | 0.83 | KDM4E (0.67) | KDM4ETDP1GAAALDH1A1MAPT | |
| SCHEMBL6635773 | 0.83 | KDM4E (0.60) | KDM4ETDP1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1083199-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORP (JP) | 2006-08-02 | — | — | EP | claimed |
| US-20240317978-A1 | RUBBER COMPOSITION AND TIRE | OTSUKA CHEMICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-117561303-A | Rubber composition and tire | 大塚化学株式会社 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023277057-A1 | RUBBER COMPOSITION AND TIRE | 大塚化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
| EP-1083199-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORP (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-0909788-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRES | BRIDGESTONE CORP (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1420044-A2 | Rubber composition and pneumatic tire | Bridgestone Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6506849-B1 | Natural or synthetic rubber; maleimide compound; and polyaniline, hydrazide and/or amine compound; workability, elasticity | BRIDGESTONE CORPORATION (JP) | 2003-01-14 | — | — | US | disclosed |
| US-6380288-B1 | LOW HEAT GENERATION PROPERTY, AGING REISTANCE, ALSO FOR PRODUCING VIBRATION ISOLATORS, BELTS AND HOSES AS WELL AS TIRE MATERIALS SUCH AS TIRE TREADS, UNDERTREADS, CARCASSES, SIDE WALLS AND BEADS | BRIDGESTONE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-1083199-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORPORATION (JP) | 2001-03-14 | — | — | EP | disclosed |
| EP-0909788-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRES | Bridgestone Corporation (JP) | 1999-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | KDM4E 3169/4885TDP1 3641/4885GAA 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.